Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – Here’s Why

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $16.59, but opened at $17.2450. Daiichi Sankyo shares last traded at $17.27, with a volume of 1,553 shares trading hands.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 5th. One analyst has rated the stock with a Hold rating, According to MarketBeat, the stock presently has a consensus rating of “Hold”.

Get Daiichi Sankyo alerts:

View Our Latest Analysis on DSNKY

Daiichi Sankyo Price Performance

The company has a debt-to-equity ratio of 0.18, a current ratio of 2.42 and a quick ratio of 1.64. The company has a 50 day moving average price of $16.36 and a 200 day moving average price of $18.05. The firm has a market cap of $32.08 billion, a PE ratio of 18.32, a PEG ratio of 2.88 and a beta of -0.17.

Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.15 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). The firm had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.74 billion. Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.75%. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. Sell-side analysts expect that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.96 EPS for the current fiscal year.

About Daiichi Sankyo

(Get Free Report)

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.

Featured Articles

• Five stocks we like better than Daiichi Sankyo
• GE Aerospace Faces a Prove-It Moment in Q2 Earnings
• Sandisk: What the Chart Is Trying to Tell Us
• 3 Picks-and-Shovels Stocks Powering the Humanoid Robotics Buildout
• J.B. Hunt Stock Could Reach $340 as Trucking Capacity Shrinks

Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.